Disturbing Discovery Regarding Alzheimer’s May Restrict Treatment Opportunities

A recent investigation published in Neurology explored the eligibility of individuals diagnosed with atypical Alzheimer’s disease for anti-amyloid therapies such as lecanemab and donanemab. The study involved an analysis of 184 patients whose conditions were verified through medical evaluations. Depending on the criteria applied, between 70% and 85% would have been deemed ineligible for treatment. The primary factor for exclusion was cognitive assessment scores, which accounted for 50% to 67% of the cases. These results indicate that the current treatment guidelines may not properly represent the severity of the disease in those experiencing symptoms related to vision, language, planning, or movement. Additional studies may be necessary to refine eligibility evaluations.
Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated